



TTY Biopharm 4105

2025 Operational Results Report



2026.03.25

Disclaimer

This presentation contains certain forward-looking statements.

These forward-looking statements may be identified by words such as 'believes', 'expects', 'anticipates', 'projects', 'intends', 'should', 'seeks', 'estimates', 'future' or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation, among others:

- 1 pricing and product initiatives of competitors;
- 2 legislative and regulatory developments and economic conditions;
- 3 delay or inability in obtaining regulatory approvals or bringing products to market;
- 4 fluctuations in currency exchange rates and general financial market conditions;
- 5 uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side-effects of pipeline or marketed products;
- 6 increased government pricing pressures;
- 7 interruptions in production
- 8 loss of or inability to obtain adequate protection for intellectual property rights;
- 9 litigation;
- 10 loss of key executives or other employees; and
- 11 adverse publicity and news coverage.

TTY Biopharm cautions that this foregoing list of factors is not exhaustive. There may also be other risks that management is unable to predict at this time that may cause actual results to differ materially from those in forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. TTY Biopharm undertakes no obligation to update publicly or revise any forward-looking statements. Any statements regarding earnings growth is not a profit forecast and should not be interpreted to mean that TTY Biopharm's earnings or earnings per share for this year or any subsequent period will necessarily match or exceed published earnings or earnings per share forecasts of TTY Biopharm Company Limited.

01 2025 Operational Highlights



TTY Strategy Enhances Operational Performance

Operational Results Report



Revenue Overview

Consolidated Revenue
YoY growth +9.5% **6.45 billion**
Record High

Consolidated Operating Profit
YoY growth +22.2% **1.70 billion**
Record High

EPS
YoY growth +7.6% **NT\$6.27**
Record High

Unit : Million




Market Development Highlights

Operational
Results Report

2025
Operational
Highlights

2025
Financial
Performance

2026 Outlook



Strong growth in overseas sales

Lipo-AB's sales in the US is steadily increasing, and its market share in the US continues to grow. The cumulative US export share for 2025 is approximately 8.6%.*

Flu vaccine sales driven both public & private funded

Increased proportion of public funded; significant growth in the self-funded market; adjuvant vaccines targeting the mature market of aged 50 and above.

Significant Achievements in Self-Developed and Domestically Produced New Drugs

The new antibiotic Bobimixyn has been launched, meeting the needs of later-line clinical trials.

*TTY Consolidated Net Sakes Ratio.

Export Share of Operations

Operational Results Report


2025 Operational Highlights

2025 Financial Performance


2026 Outlook

Overseas revenue with an annual growth rate of 24.5%
US market with an annual growth rate of 46.2%.

Unit : Million



Consolidated Revenue by Countries



Three Arrows of Operation with Outstanding Results

Operational
Results Report

2025
Operational
Highlights

Export
Difficulty
Generic Drugs

Launch the Drug Licenses Submission Globally

- ▶ New equipment to meet the capacity expansion needs of the US sales growth.
- ▶ Passed US factory inspection.
- ▶ Saudi Arabia, Australia, Vietnam, the Philippines, Jordan, and Hong Kong have applied licenses and registration procedures for submitted documents.

2025
Financial
Performance

License-in
International New
Drugs

Access to Global Therapies

- ▶ Minjuvi, new treatment options for Lymphoma launched.
- ▶ Asia's first adjuvanted flu vaccine to be funded by the government in 2026.
- ▶ In line with the EU, adjuvanted flu vaccines will be available to adults aged 50 and over in 2026.
- ▶ Introducing the TTY_B varicella vaccine by participate in government tenders in 2026.

2026 Outlook

Self-developed
New Drugs/
Generic Drugs

Cross-Border Corporate Collaboration

- ▶ Product Strategy Alliance on Avastin/Rozlytrek.
- ▶ Xpovio has been granted distribution rights offers a complete product line for hematoma treatments.

Strengthened Supply Resilience

- ▶ First domestically developed targeted lung cancer drug, Pulmivex, received license in Q1/2026.
- ▶ Fustron, a new breast cancer treatment is covered by NHI, and a record-breaking achievement.
- ▶ Bobimixyn, the first new antibiotic drug, with impressive marketing performance.
- ▶ Algitab Chewable Tablets received medical association treatment consensus.

Emerging Combination Therapy Trends

- ▶ Self-made product, Pexeda combined with IO therapy (Keytruda).
- ▶ Self-made Leavdo+Minjuvi monoclonal antibody.


Product Pipeline: Self-develop, License-in, Cooperation

Operational
Results Report

2025
Operational
Highlights

2025
Financial
Performance

2026 Outlook



Note: those without marked are in Taiwan.

02 2025 Financial Performance



2025 Financial Performance

Operational Results Report

2025
Operational
Highlights

2025
Financial
Performance

2026 Outlook

Income Statement (Unit: NT Thousand, except EPS)	2025	2024	YoY Differences	YoY %
Net Sales	6,452,948	5,893,847	559,101	9.5%
Operating Cost	2,732,425	2,479,113	253,312	10.2%
Gross Profit	3,720,553	3,416,171	304,382	8.9%
Gross Margin (%)	57.7%	57.9%		
Operating Expenses	2,016,594	2,022,315	-5,721	-0.3%
Operating Profit	1,703,959	1,393,856	310,103	22.3%
Operating Margin (%)	26.4%	23.6%		
Non-operating Income	421,219	491,831	-70,612	-14.4%
Profit before Tax	2,125,178	1,885,687	239,491	12.7%
Net Income (Consolidated)	1,654,704	1,519,354	135,350	8.9%
Net Margin (%)	25.6%	25.8%		
Net Profit Attributable to Owners of the Parent Company	1,559,125	1,449,622	109,503	
EPS (Unit : NTD)	6.27	5.83		

Financial Performance

- YoY consolidated revenue was 6.45 billion, +9.5% due to the high growth of overseas markets, a significant contribution of influenza vaccines to Intensive Care BU, and Oncology BU and reinvestment increased steady as well.
- YoY consolidated operating gross profit at 57.7%, and it's about the same as the period last year.
- Non-operating income decreased by 14.4%, due to the recognition of settlement in overseas markets in 2025, and PharmaEngine achieved a sales milestone of \$50 million in licensing fees.
- Net income after tax was 1.65 billion, and the net profit attributable to owners of the parent company was 1.56 billion, and EPS was NT\$6.27, representing a year-over-year increase of NT\$0.44.

2025 Steady Revenue Growth


Operational
Results Report

2025
Operational
Highlights


**2025
Financial
Performance**

2026 Outlook

2025 Revenue Breakdown



2025 Revenue Growth





2025 Key Performance

Operational
Results Report

2025
Operational
Highlights

2025
Financial
Performance

2026 Outlook



Excellent Performance

- TOP 5% of TPEX-listed companies in the Company Governance Evaluation.
- In 2025, the company reached a record-high net profit of NTD 1,559 million (USD 49.9 million), EPS of 6.27, and accompanied by a gross margin of 57.7%.

3 consecutive years

Gold Awards in the Healthcare Category 1 of the TCSA Sustainability Report

104 Job Bank

Best Employer Attraction Award in 2024

Winner Announcement

Asia Pacific Enterprise Awards (APEA) 2025, Taiwan

03 2026 Outlook



2026 Outlook



Operational
Results Report

2025
Operational
Highlights

2025
Financial
Performance

2026 Outlook

1 Expanding collaboration & overseas market

- **Lipo-AB:**
 - Expected to obtain licenses from Saudi Arabia, Australia, and Jordan
 - Deploy the market in Southeast Asia and South America
- **Leavdo launched in Singapore**
- **Continue to cultivate Southeast Asian markets such as Vietnam and South Korea**

2 Licensing In & Self-developed

- **Deepen cooperation with international factories**
- **Launch licensing-in products annually, expanding operational performance**
 - New drug of lung cancer, Pulmivex launched
 - Achieved blood cancer drug, Xpovio's distribution
- **Self-developed new products**
 - Launched antibiotics DP and TZ are on the market
- **Establish domestic technology transfer model**


3 Cost Reduction & Process Improvement

- **Implementing ERP (SAP) to optimized and improved operational efficiency continuously.**
- **Supply chain management**
- **Expanding production capacity in response to future market demand**

Vaccine Field

Comprehensive vaccine portfolio to support public health

Create an all-age influenza vaccine product line and become the market leader



Operational Results Report

2025 Operational Highlights

2025 Financial Performance

2026 Outlook

OkaBIK Varicella Vaccine

Operational
Results Report

2025
Operational
Highlights

2025
Financial
Performance

2026 Outlook



Taiwan Selection

In addition to distributing CSL Seqirus cell influenza vaccine and adjuvanted influenza vaccine, TTY continues to expand distribution to include BIKEN's varicella vaccine.

First approved in Japan in 1984, it has been used for 40 years. Currently, most varicella vaccines used worldwide are still based on the Oka strain.



Oka Strain



Suitable for children 12 months and older

Immunization of children over 12 months of age, adolescents and adults to prevent chickenpox infection.

The varicella vaccine is a routine vaccine, with the first dose subsidized by the government. Bidding will commence in Q2/2026, and supply is expected to begin in Q1/2027.



publicly funded market for chickenpox vaccines